\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Rare Primary Paraovarian Adenocarcinoma in Postmenopausal Woman: Case Report and Review}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2019 2019-01-15 (revised: 9 Year 2019 15 January 2019)} \def\TheID{\makeatother } \def\TheDate{2019 2019-01-15} \title{Rare Primary Paraovarian Adenocarcinoma in Postmenopausal Woman: Case Report and Review} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Dr. Anjani Dixit} \author[2]{Dr. Shanti Jayaseelan} \renewcommand\Authands{ and } \date{\small \em Received: 9 December 2018 Accepted: 4 January 2019 Published: 15 January 2019} \maketitle \begin{abstract} Malignant paratubal cancers have extremely rare occurrence and have not been sufficiently described and discussed in literature. We describe case of an 80 years old gravida 5 para 4 postmenopausal woman presented with pain in lower abdomen and spotting per vagina. USG followed by MRI showed large mid pelvic right adnexal complex predominantly cystic lesion of 8.7x7.1x5.9 cm size with small exophytic solid component (3.1x2.8x2.6 cm). Postoperatively it was diagnosed as a case of high grade paratubal adenocarcinoma (stage T1N0M0). The patient received 3 cycles of adjuvant chemotherapy with carboplatin and docetaxel. Patient has had no recurrence till date (20 months post treatment). \end{abstract} \keywords{Paratubal adenocarcinoma, adnexal complex, primary tumour, broad ligament.} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \section[{Introduction}]{Introduction}\par rimary paraovarian malignancy is an extremely rare condition, so much so that very little is known about their epidemiology, biological behaviour, prognosis, protocols for diagnosis and management. The incidence of paraovarian malignancy is also not known \hyperref[b15]{16} . Very few cases have been reported in literature till date. We hereby present, to the best of our knowledge, the oldest patient in literature with pain in lower abdomen for last one and a half year and vaginal spotting for last 4 days. Patient was menopausal for last 30 years. On pelvic examination, cervix and vagina were assessed to be normal, uterus was normal and anteverted, a cystic mass of approximately 6x6 cm in size was felt close to uterus, and POD was free. USG was suggestive of thin walled anechoic cystic mass on right side, 8x6x6 cm with few internal septae. MRI pelvis showed large midpelvic right adnexal complex predominantly cystic lesion of size 8.7 x 7.1 x5.9 cm with small exophytic solid component (3.1x2.8x2.6 cm). The exophytic solid component was focally indenting anterior rectal wall with no apparent infiltration. Endometrial thickness was 1.7 mm, smooth regular margins and fluid -fluid levels were seen. Endometrial curettage was done and histopathology report showed senile endometrium. Her serum CA125 level was normal.\par Patient underwent exploratory laparotomy. No ascites or peritoneal implants were seen. Peritoneal wash was sent for cytological examination. Both the ovaries, fallopian tubes and the uterus were normal in appearance. A large paraovarian cystic mass measuring 8x6x4cm was seen on right side with right fallopian tube stretched over it. TAH with BSO with cystectomy was done. Full biochemical and radiological examinations showed no evidence of metastasis or any other disease process. We staged the primary paraovarian tumour as T1aN0M0. Five weeks later, patient underwent 3 cycles of adjuvant chemotherapy with carboplatin and docetaxel. Patient is doing well in follow up visits till date (20 months post treatment). \section[{III.}]{III.} \section[{Pathology}]{Pathology}\par On postsurgical examination, peritoneal fluid cytology showed no evidence of malignancy. On macroscopic examination, paraovarian cyst was found to be uniloculated, filled with thin hemorrhagic fluid and a firm, greyish white nodule measuring 3x2.5x2 cm was seen in the wall of the cyst, which on cut surface was grey white, granular with large areas of necrosis. Rest of the cyst wall had smooth inner surface with foci of hemorrhages. No tumour was found in the bilateral ovaries and fallopian tubes. Microscopic examination of the right adnexal mass revealed malignant tumour with solid and tubulocystic pattern with cells lining the tubules having hobnail appearance. There was marked pleomorphism in the neoplastic cells in the solid area suggestive of high grade serous adenocarcinoma from paraovarian cyst (Fig. \hyperref[fig_1]{1 and 2}). Large areas of necrosis and stromal lymphocytic infiltration were seen. Sections of the cyst wall showed columnar to cuboidal to flattened cell lining with underlying fibrosis and infiltration by hemosiderin laden macrophages. There was no lymphovascular space invasion. Endomyometrium showed senile cystic atrophy with atrophic myometrium. Bilateral fallopian tubes and ovaries were unremarkable. \section[{Discussion}]{Discussion}\par Secondary tumours in broad ligament are not uncommon but primary tumours are rare. Commonly seen primary tumours are leiomyomata, serous and papillary cystadenoma of borderline malignancy but primary malignant tumours are very rare \hyperref[b8]{9} . Primary broad ligament carcinoma as mesonephroma was first reported by Schiller in 1939 \hyperref[b0]{1} .\par In our case primary tumour was located in or on the broad ligament and completely separated from ipsilateral ovary, fallopian tube, and uterus. This satisfies the criteria given by Gardner et al in 1957 to diagnose primary carcinoma of broad ligament origin \hyperref[b3]{4} .\par The age range in reported cases of broad ligament malignant tumours is 13 to 80 years (median 43 years) and the age range of borderline below the age of 40 years. To the best of our knowledge, ours (80 years) is the oldest case reported in the literature. In contrast, mean age of ovarian cancer is 63 years, being rare in women below 40 years \hyperref[b17]{18} and mean age of borderline ovarian tumours is 10 years lower \hyperref[b18]{19} .\par Five were clear cell carcinoma (20.8\%), two were papillary adenocarcinoma (8.3\%), four were endometroid (16.6\%), five including ours were serous adenocarcinoma (20.8\%), one was mucinous carcinoma (4.1\%), and one was well differentiated adenocarcinoma (4.1\%) and five were borderline serous cystadenoma (20.8\%) (Table \hyperref[tab_0]{1}).\par Most common presenting symptoms reported are lower abdominal pain and pelvic discomfort \hyperref[b14]{15} like in our case. Moreover, our patient also presented with vaginal spotting. Although most common cause for vaginal spotting in post-menopausal age group is senile endometritis \hyperref[b19]{20} , there is a possibility of associated Hence it is important to rule out endometrial cancer in scenarios of vaginal spotting for postmenopausal women. In our case endometrial cancer was ruled out by endometrial curettage. It is to be noted that presentation of broad ligament tumour can be an incidental finding as well \hyperref[b8]{9} . There is a 1.4 \% to 3.8\% chance of synchronous tumour of ovary and endometrium \hyperref[b19]{20} but similar data about broad ligament tumour is not known due to rarity of cases. All the reported cases of broad ligament tumour (Table \hyperref[tab_0]{1}) including borderline variety were unilateral, in contrast to ovarian tumour which are 25\% bilateral \hyperref[b20]{21} .\par For fourteen cases (58\%) including ours, patients were diagnosed in stage 1 of broad ligament tumour. Two cases (8.3\%) were diagnosed in stage 2, while three cases (12.5\%) were diagnosed in stage 3. Staging was not known for the remaining five cases (20.8\%). It is to be noted that majority of the cases, including our case, were diagnosed in stage 1. Possible reason for the same is that tumours are encapsulated between the sheets of broad ligament. Thus rupture as well as aggressive progression is prevented due to lack of vasculature \hyperref[b21]{22} .\par Management of broad ligament tumour is often done in a similar way as that of ovarian cancer because of similarities in histology and histogenesis, i.e. commonality in coelomic epithelium \hyperref[b9]{10} . Post-surgical adjuvant treatment is not established as the standard procedure due to lack of evidence. It is recommended to use same principles as followed in the management of ovarian cancer \hyperref[b14]{15} . Of the 24 cases, surgery was the singular mode of treatment in eleven cases (46\%), surgery followed by chemotherapy in eight cases including our case (33\%), surgery followed by radiotherapy in four cases (17\%) while only radiotherapy was used in one case (4\%). \section[{Conclusion}]{Conclusion}\par Survival rates and prognostic factors are inconclusive due to rarity of the tumour, lack of uniformity in treatment modalities and improper reporting. Similar to cases of ovarian cancer, follow up is important to look for relapse or any residual disease left after adjuvant therapy.\par We recommend that such rare cases be reported in literature so that consensus on diagnosis and management can be evolved and established.\begin{figure}[htbp] \noindent\textbf{}\includegraphics[]{image-2.png} \caption{\label{fig_0}}\end{figure} \begin{figure}[htbp] \noindent\textbf{1}\includegraphics[]{image-3.png} \caption{\label{fig_1}Fig. 1}\end{figure} \begin{figure}[htbp] \noindent\textbf{1} \par \begin{longtable}{P{0.046816881258941345\textwidth}P{0.14531473533619454\textwidth}P{0.027968526466380546\textwidth}P{0.05958512160228898\textwidth}P{0.1623390557939914\textwidth}P{0.25171673819742485\textwidth}P{0.13984263233190272\textwidth}P{0.016416309012875538\textwidth}} \multicolumn{2}{l}{S. No. Author (year)}\tabcellsep Age (years )\tabcellsep Size (cm)\tabcellsep Pathological diagnosis\tabcellsep Treatment\tabcellsep Follow up\tabcellsep stage\\ 1\tabcellsep Schiller 1 (1939)\tabcellsep 43\tabcellsep Child's head\tabcellsep Clear cell\tabcellsep TAH+BSO, Radiotherapy\tabcellsep Live, 24 months\tabcellsep 1\\ 2\tabcellsep Lennox 2 (1952)\tabcellsep 45\tabcellsep 7x6.5x6\tabcellsep Papillary adenocarcinoma\tabcellsep TAH+BSO, Radiotherapy\tabcellsep Live, 10 months\tabcellsep 1\\ 3\tabcellsep Telium 3 (1954)\tabcellsep 62\tabcellsep Fist size\tabcellsep Clear cell\tabcellsep Enucleation\tabcellsep Not known\tabcellsep 2\\ 4\tabcellsep Telium 3 (1954)\tabcellsep 32\tabcellsep 10x8x8\tabcellsep Clear cell\tabcellsep Enucleation\tabcellsep Not known\tabcellsep 1\\ 5\tabcellsep Gardner 4 (1957)\tabcellsep 50\tabcellsep -\tabcellsep Well differentiated adenocarcinoma\tabcellsep Radiotherapy\tabcellsep Live,27 months\tabcellsep --\\ 6\tabcellsep Merril 5 (1959)\tabcellsep 70\tabcellsep 13\tabcellsep Papillary adenocarcinoma\tabcellsep TAH+BSO, Radiotherapy\tabcellsep Live,12 months\tabcellsep 2\\ 7\tabcellsep Czernobilsky 6 (1972)\tabcellsep 29\tabcellsep 5x4x4\tabcellsep LMP Serous\tabcellsep TAH+BSO\tabcellsep Not known\tabcellsep 1\\ 8\tabcellsep Genadry 7 (1977)\tabcellsep 13\tabcellsep 9x6\tabcellsep Serous adenocarcinoma\tabcellsep Adnexectomy\tabcellsep Live, 60 months\tabcellsep --\\ 9\tabcellsep Genadry 7 (1977)\tabcellsep 38\tabcellsep 9x6\tabcellsep LMP Serous\tabcellsep Adnexectomy\tabcellsep Live, 60 months\tabcellsep --\\ 10\tabcellsep Genadry 7 (1977)\tabcellsep 36\tabcellsep 9x6\tabcellsep LMP Serous\tabcellsep Adnexectomy\tabcellsep Live, 60 months\tabcellsep --\\ 11\tabcellsep Genadry 7 (1977)\tabcellsep 28\tabcellsep 9x6\tabcellsep LMP Serous\tabcellsep Adnexectomy\tabcellsep Not known\tabcellsep --\\ 12\tabcellsep Clark 8 (1979)\tabcellsep 29\tabcellsep 8x7x2\tabcellsep Mucinous adenocarcinoma\tabcellsep TAH+BSO+ omentectomy\tabcellsep Not known\tabcellsep 1\\ \multicolumn{2}{l}{13 Aslani 9 (1989)}\tabcellsep 51\tabcellsep 10x6x6\tabcellsep Clear cell\tabcellsep Excision+BSO+ omentectomy, Radiotherapy\tabcellsep Live, 7 months\tabcellsep 1\\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Excision+TAH+BSO,\tabcellsep \tabcellsep \\ \multicolumn{2}{l}{14 Aslani 9 (1989)}\tabcellsep 29\tabcellsep 6x6x5\tabcellsep Endometroid\tabcellsep inguinal and paraaortic lymph node sampling,\tabcellsep Live, 18 months\tabcellsep 1\\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Chemotherapy\tabcellsep \tabcellsep \\ 15\tabcellsep Aslani 9 (1989)\tabcellsep 69\tabcellsep 11x8\tabcellsep Endometroid\tabcellsep Excision of tumor + TAH+BSO, Chemotherapy\tabcellsep Live, 12 months\tabcellsep 1\\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep TAH+BSO+ plevic\tabcellsep \tabcellsep \\ 16\tabcellsep Aslani 9 (1989)\tabcellsep 34\tabcellsep 4.5x4x3.5\tabcellsep Endometroid\tabcellsep and paraaortic lymph node dissection+ omentectomy,\tabcellsep Live, 6 months\tabcellsep 1\\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Chemotherapy\tabcellsep \tabcellsep \\ 17\tabcellsep Altaras 11 (1990)\tabcellsep 76\tabcellsep 12x9x8\tabcellsep Serous\tabcellsep TAH+BSO\tabcellsep Live, 53 months\tabcellsep 1\end{longtable} \par \caption{\label{tab_0}Table 1 :}\end{figure} \backmatter \begin{bibitemlist}{1} \bibitem[Schiller and Mesonephromaovarii ()]{b0}\label{b0} \textit{}, W Schiller , Mesonephromaovarii . \textit{Am J Cancer} 1939. 35 p. . \bibitem[Lennox et al. (1952)]{b1}\label{b1} \textit{}, B Lennox , D J Meagher , Parovarian . \textit{BJOG: An International Journal of Obstetrics \& Gynaecology} 1952 Dec 1. 59 (6) p. . \bibitem[Berek and Berek & Novak's Gynecology ()]{b19}\label{b19} \textit{}, J S Berek , Berek \& Novak's Gynecology . 2012. Philadelphia, USA: Lippincott Williams \& Wilkins. 15. (th ed.) \bibitem[(no date) Ovarian Cancer Risk Factors]{b17}\label{b17} \textit{(no date) Ovarian Cancer Risk Factors}, \url{https://www.cancer.org/cancer/ovarian-cancer/causes-risks-prevention/risk-factors.html} American Cancer Society. (accessed on 22 july 2018) \bibitem[Czernobilsky and Lancet (1972)]{b5}\label{b5} \textit{Broad ligament adenocarcinoma of Müllerian origin. Obstetrics \& Gynecology}, B Czernobilsky , M Lancet . 1972 Aug 1. 40 p. . \bibitem[Merrill (1959)]{b4}\label{b4} ‘Carcinoma of the broad ligament’. J Merrill . \textit{Obstetrics \& Gynecology} 1959 Apr 1. 13 (4) p. . \bibitem[Clark et al. (1979)]{b7}\label{b7} ‘Endometrioid-type cystadenocarcinoma arising in the mesosalpinx’. J E Clark , H Wood , W J Jaffurs , S Fabro . \textit{Obstetrics and gynecology} 1979 Nov. 54 (5) p. . \bibitem[Handa et al. (2007)]{b21}\label{b21} ‘High-grade broad ligament cancer of müllerian origin: immunohistochemical analysis of a case and review of the literature’. Y Handa , H Kato , M Kaneuchi , Y Saitoh , K Yamashita . \textit{International Journal of Gynecological Cancer} 2007 May. 17 (3) p. . \bibitem[Telium ()]{b2}\label{b2} ‘Histogenesis and classification of mesonephric tumours of the female and male genital system and relationship to benign so called adenomatoid tumours (mesothelioma)’. G Telium . \textit{Acta Pathol Microbiol Scand} 1954. 34 p. 431. \bibitem[Itani et al. (2002)]{b10}\label{b10} \textit{Malignant epithelial tumor of unknown origin of the broad ligament. Archives of gynecology and obstetrics}, Y Itani , K Itoh , S Adachi , M Koyama , T Kimura , R Chin , T Takemura . 2002 Dec 1. 267 p. . \bibitem[Green and Huh (2012)]{b18}\label{b18} \textit{Online document at: www.emedicine.medscape.com/Accessed}, A E Green , W Huh . August. 2012 Aug 18. 18. (Borderline Ovarian Cancer: Borderline Tumor Overview) \bibitem[Savelli et al. (2006)]{b16}\label{b16} \textit{Paraovarian/paratubal cysts: comparison of transvaginal sonographic and pathological findings to establish diagnostic criteria}, L Savelli , T Ghi , De Iaco , P Ceccaroni , M Venturoli , S Cacciatore , B . 2006 Sep 1. 28 p. . (Ultrasound in obstetrics \& gynecology) \bibitem[Vaysse et al. (2009)]{b11}\label{b11} ‘Paratubalendometrioidcystadenocarcinoma: case report and review’. C Vaysse , J Capdet , E Mery , D Querleu . \textit{Eur J GynaecolOncol} 2009 Jan 1. 30 (4) p. . \bibitem[Kim and Cho (2015)]{b13}\label{b13} \textit{Primary borderline parovarian tumor in pregnancy. Obstetrics \&gynecology science}, J H Kim , D H Cho . 2015 Nov 1. 58 p. . \bibitem[Kaur et al. (2014)]{b12}\label{b12} \textit{Primary endometrioid carcinoma of the broad ligament: a rare case report. The Journal of Obstetrics and Gynecology of India}, N Kaur , R Kaushik , A Gulati , V Kaushal , R Bindra . 2014 Feb 1. 64 p. . \bibitem[Altaras et al. (1990)]{b9}\label{b9} \textit{Primary paraovariancystadenocarcinoma: clinical and management aspects and literature review. Gynecologic oncology}, M M Altaras , R Jaffe , M Corduba , M Holtzinger , C Bahary . 1990 Aug 1. 38 p. . \bibitem[Miyoshi et al. (2016)]{b14}\label{b14} \textit{Rare Primary Adenocarcinoma of the Broad Ligament: Report of Two Cases and a Literature Review. International journal of surgical pathology}, A Miyoshi , T Miyatake , T Hara , S Komiya , N Komura , A Tanaka , S Kanao , M Takeda , M Mimura , M Nagamatsu , M Yamasaki . 2016 Aug. 24 p. . \bibitem[Aslani and Scully (1989)]{b8}\label{b8} \textit{Report of four cases and review of the literature. Cancer}, M Aslani , R E Scully . 1989 Oct 1. 64 p. . (Primary carcinoma of the broad ligament) \bibitem[Genadry et al. ()]{b6}\label{b6} ‘The origin and clinical behaviour of the paraoavrian tumour’. R Genadry , T Parmley , J Woodruff . \textit{Am J ObstetGynecol} 1977. 129 p. . \bibitem[Micci et al. ()]{b20}\label{b20} ‘Tumor spreading to the contralateral vary in bilateral ovarian carcinoma is a late event in clonal evolution’. F Micci , L Haugom , T Ahlquist , V M Abeler , C G Trope , R A Lothe , S Heim . \textit{Journal of oncology} 2010. 2010. \bibitem[Gardner et al. (1957)]{b3}\label{b3} ‘Tumors of the broad ligament’. G H Gardner , R R Greene , B Peckham . \textit{Obstetrical \& Gynecological Survey} 1957 Oct 1. 12 (5) p. . \bibitem[Yoonessi ()]{b15}\label{b15} M Yoonessi . \textit{Carcinoma of the fallopian tube}, 1979. p. 257. \end{bibitemlist} \end{document}